- Home | GSK US
Ben Schwartz, VP of Oncology, shares his 20-year GSK journey, from drug discovery to leading research Addressing Long-Standing Barriers to Adult Immunization Our COiMMUNITY Initiative fosters a systematic, collaborative, and approach to boost vaccinations
- Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together We aim to positively impact the health of 2 5 billion people by the end of the decade, as a successful, growing company where people can thrive
- Nucala (mepolizumab) approved by US FDA for use in adults with chronic . . .
GSK plc (LSE NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype
- ViiV Healthcare continues to deliver long-acting injectable HIV . . .
GSK plc (LSE NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will be presenting abstracts from its innovative HIV treatment and prevention portfolio and research pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025)
- Purpose, strategy and culture | GSK US
GSK is a company where outstanding people can thrive We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease At the heart of this is our R D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in
- Press releases | GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer
- Products - GSK US
In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center Our product areas Specialty medicines
- Respiratory, immunology and inflammation | GSK US
GSK plc Registered in England and Wales No 3888792 Registered office: 79 New Oxford Street, London United Kingdom WC1A 1DG GSK websites; GSK Global website; Locations selector; Global Behind the science; GSKPro for HCPs; ViiV Healthcare; GSK study register; Business to Business; Quick links; Behind the science US edition;
|